Researchers track Long-Term risks of experimental cancer treatment
NCT ID NCT06887348
First seen Jan 12, 2026 · Last updated May 15, 2026 · Updated 20 times
Summary
This study monitors patients who have already received at least one dose of Replimune's experimental cancer therapy (RPx) for up to 5 years. The goal is to identify any delayed side effects or infections related to the treatment. No new drugs are given—participants simply provide follow-up health information. The study includes people with melanoma, advanced solid tumors, or liver cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tasman Oncology Research
RECRUITINGSouthport, Queensland, 4215, Australia
Contact
-
UC San Diego Moores Cancer Center
RECRUITINGLa Jolla, California, 92093-0698, United States
Contact
Conditions
Explore the condition pages connected to this study.